Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a master distributor agreement with AD Ports Logistics (ADPL), a subsidiary of the Logistics Cluster, AD Ports Group, a leading global facilitator of trade, logistics and industry based in Abu Dhabi (ADX: ADPORTS). The master distributor agreement covers the distribution of ZTlido® in the United Arab Emirates, Qatar, Bahrain, Kuwait, Oman, and Egypt.
ZTlido® is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN). ZTlido® was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.
“We are delighted to work with our partners at Scilex to enable access to some of the most innovative pain management medications on the market today by leveraging our advanced GDP-certified pharma logistics network and the unique capabilities of our Healthcare & Life Sciences Team. Collaborative partnerships such as these play an important role in helping further the quality of healthcare services in the UAE and the broader region and deliver on our leadership’s vision of establishing Abu Dhabi as a center for local, regional, and global healthcare and life science excellence,” said Farook Al Zeer, Chairman, Logistics Cluster, AD Ports Group.
“We are pleased to announce this master distributor agreement, which represents another critical milestone towards bringing our innovative non-opioid pain management medicines to the Middle East and North Africa region and further our commitment of establishing Abu Dhabi as a global life sciences hub,” said Jaisim Shah, Chief Executive Officer and President of Scilex.